Cytokinetics, Incorporated (CYTK) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 8.62B USD. 52-week range 54.30 to 88.31 USD. Data as of 2026-10-09.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a ...